~~<i id='E69F757BE7'><strike id='E69F757BE7'><tt id='E69F757BE7'><pre id='E69F757BE7'></pre></tt></strike></i>~~

Home» leisure time» comprehensive

comprehensive

author：Wikipedia 2025-09-28 04:24:08 Page View：39

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medtronic CEO on promising devices for diabetes, hypertension
Next article： New air purifier tech could be key to improving indoor air quality

explore

In age of alternative facts, a scholarly course on calling out crap

Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

Biden's order seeks to regulate AI risk without stifling innovation

AdobePresidentBidenorderedthenation’sleadinghealthagenciesonMondaytodevelopaplanforregulatingartific

Cancer drug shortages should be causing more outrage

DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

The FDA weighs the risks of candy

AdobeWASHINGTON—M&Ms,Reese’s,gummybears,andevencottoncandymadeanappearanceattheFoodandDrugAdmini